The goal of this activity is for learners to be better able to describe the latest phase 3 clinical data evaluating therapies for transthyretin amyloid cardiomyopathy and its relevance for future clinical practice.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1002007
- Start Date: 2024-12-16 06:00:00
- End Date: 2024-12-16 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: BridgeBio - Amount: 171513.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Cardiovascular Disease
Subscribe
Login
0 Comments
Oldest